Sign In
Buy MRK
$113.87
-1.62 (-1.40%)
At Close: Jun 18, 2026
A Look at Pharma ETFs After Q4 Earnings
02:01pm, Monday, 12'th Feb 2024
The fourth-quarter results of the healthcare sector have been unimpressive, with earnings of companies that have reported so far down 17.7% despite 7% revenue growth. However, many industry bigwigs re
Here's Why Merck, Eli Lilly, and Novo Nordisk Stocks Rose 11% Last Month
04:56pm, Thursday, 08'th Feb 2024
Demand is surging for weight-loss treatments that are being rolled out by major pharmaceutical companies. Investors are still trying to assess the full market opportunity and competitive landscape.
J&J, Merck and Bristol Myers CEOs, under fire on Capitol Hill, seek to turn up heat on drug-market middlemen
03:29pm, Thursday, 08'th Feb 2024
Drugmakers grilled on the cost of prescription drugs on Capitol Hill Thursday sought to deflect the criticism onto drug-market middlemen who they said are pushing list prices for medications higher.
US Senate Democrats grill pharma CEOs on drug prices
03:18pm, Thursday, 08'th Feb 2024
U.S. Senate Democrats grilled three top pharmaceutical executives over the high cost of prescription drugs on Thursday but failed to extract any commitments from them to lower prices.
Pharma CEOs Will Testify Today Over Prescription Drug Prices: Here's What To Watch For
10:28am, Thursday, 08'th Feb 2024
Chief executives from three major pharmaceutical companies will testify before a Senate committee on Thursday, following a back-and-forth with Sen. Bernie Sanders (I-Vt.
Senators to question Merck, J&J and Bristol Myers Squibb CEOs over high U.S. drug pricing
07:00am, Thursday, 08'th Feb 2024
The push to cut drug prices is one of those rare hot-button issues that unites the two major political parties.
Merck, J&J and Bristol Myers CEOs face drug-pricing grilling on Capitol Hill, but experts cite deeper problems under the radar
02:08pm, Wednesday, 07'th Feb 2024
Lawmakers seeking to hold drugmakers accountable for high prescription-drug costs are focusing on some prices that shed little light on the problem, drug-pricing experts say.
Merck (MRK) Unit to Buy Elanco's Aqua Business for $1.3B
11:51am, Tuesday, 06'th Feb 2024
Merck's (MRK) Animal Health unit is set to strengthen its position with the acquisition of Elanco Animal Health's aqua business for $1.3 billion. The transaction is expected to close by mid-2024.
3 companies that more than doubled analyst EPS estimates
07:22am, Tuesday, 06'th Feb 2024
Earnings season is well underway, and the winner-and-loser separation continues to grow. Of the companies that beat consensus analyst estimates, even fewer go well beyond and exceed analyst expectatio
Elanco Animal Health sells aqua business to Merck for $1.3 billion
08:24am, Monday, 05'th Feb 2024
Elanco Animal Health Inc has announced the sale of its aqua business to Merck Animal Health for US$1.3 billion in a bid to refocus on other markets. This will enable Elanco to accelerate debt paydown
Elanco Animal Health agrees to sell aqua business to Merck for $1.3 billion in cash
06:43am, Monday, 05'th Feb 2024
Elanco Animal Health Inc. ELAN, -0.41% said Monday it has agreed to sell its aqua business to Merck Animal Health MRK, +0.02% for $1.3 billion in cash. Greenfield, Ind.
3 Pharma Stocks to Sell in February Before They Crash and Burn
02:39pm, Friday, 02'nd Feb 2024
The pharma industry has developed some real blockbusters between novel vaccines and weight loss drugs over the past few years. This has increasingly led investors to view pharma stocks as a promising
Why Merck Stock Rocketed Nearly 5% Skyward Today
06:52pm, Thursday, 01'st Feb 2024
The healthcare giant published its fourth-quarter and full-year 2023 results. It beat on both the top and bottom lines for the quarter.
Merck Stock Hits Record High on Sales of Cancer Drugs, Vaccines
04:30pm, Thursday, 01'st Feb 2024
Merck & Co. (MRK) shares traded at an all-time high Thursday after the pharmaceutical company posted a surprisingly positive adjusted profit after sales jumped for its cancer drugs and vaccines.
Three-Stock Lunch: Merck, Norfolk Southern and Boot Barn
03:11pm, Thursday, 01'st Feb 2024
Jerry Castellini, CastleArk Management CIO, joins 'Power Lunch' to discuss his investing take on three stocks: Merck, Norfolk Southern, and Boot Barn.
